4.3.2.2	(S)-2-[5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido]succinate	-	
4.3.2.2	(S)-2-[5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido]succinate	the enzyme is involved in both de novo and salvage pathways of purine biosynthesis	
4.3.2.2	1-(5-phosphoribosyl)-4-(N-succinocarboxamide)-5-aminoimidazole	-	
4.3.2.2	4-(N-succino)-5-aminoimidazole-4-carboxamide ribonucleotide	reaction in the biosynthesis of AMP	
4.3.2.2	4-(N-succino)-5-aminoimidazole-4-carboxamide ribonucleotide	enzyme catalyzes two nonsequential reactions in purine biosynthesis	
4.3.2.2	5-aminoimidazole-(N-succinylocarboxamide) ribotide	-	
4.3.2.2	5-aminoimidazole-4-(N-succinylcarboxamide) ribonucleotide	-	
4.3.2.2	5-aminoimidazole-4-(N-succinylcarboxamide) ribonucleotide	first step common to both de novo and the salvage pathways in purine biosynthesis	
4.3.2.2	5-aminoimidazole-4-(N-succinylcarboxamide) ribonucleotide	i.e. SAICAR	
4.3.2.2	5-aminoimidazole-4-(N-succinylcarboxamide) ribonucleotide	the 8th step in the purine nucleotide de novo pathway	
4.3.2.2	adenylosuccinate	-	
4.3.2.2	additional information	the low activity of the enzyme in liver of severely starved rats is inconsistent with the proposal that the purine nucleotide cycle plays a major role in ammonia production for urea synthesis at least under these conditions	
4.3.2.2	additional information	roles of adenylosuccinate lyase and of AMP deaminase in the anti-HIV activity of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine	
4.3.2.2	additional information	adenylosuccinate lyase catalyzes two reactions in the biosynthesis of purine nucleotides	
4.3.2.2	additional information	adenylosuccinate lyase deficiency is a rare autosomal disorder of de novo purine synthesis, which results in the accumulation of succinylpurines in body fluids. Patients with adenylosuccinate lyase deficiency show a variable combination of mental retardation, epilepsy and autistic features, overview	
4.3.2.2	additional information	adenylosuccinate lyase deficiency is an autosomal recessive disorder of the purine de novo synthesis pathway and purine nucleotide cycleby severe neurological involvement including hypotonia, seizures, developmental delay and autistic features. Epilepsy in ADSL deficiency is frequent and occurs in approximately two-thirds of patients, beginning either early in the neonatal period or after the first year of life	
4.3.2.2	additional information	adenylosuccinate lyase is the only enzyme in the purine biosynthetic pathway that catalyzes two distinct, but chemically similar reactions	
4.3.2.2	additional information	ZMP is an activator of the AMP-activated protein kinase, AMPK, and is toxic in human B lymphocytes and neuroblastoma cell lines, physiological functions of ZMP, overview	
4.3.2.2	additional information	the activity of the Mycobacterium tuberculosis enzyme is particularly low	
4.3.2.2	N6-(1,2-dicarboxyethyl)AMP	-	
4.3.2.2	N6-(1,2-dicarboxyethyl)AMP	enzyme catalyzes the last step in the pathway of AMP biosynthesis	
4.3.2.2	N6-(1,2-dicarboxyethyl)AMP	reaction in the biosynthesis of AMP	
4.3.2.2	N6-(1,2-dicarboxyethyl)AMP	terminal step in AMP biosynthesis	
4.3.2.2	N6-(1,2-dicarboxyethyl)AMP	the enzyme is involved in both de novo and salvage pathways of purine biosynthesis	
4.3.2.2	phosphoribosylsuccinyl-aminoimidazole carboxamide	-	
4.3.2.2	succinyladenosine monophosphate	-	
4.3.2.2	succinyladenosine monophosphate	conversion of adenylosuccinate to adenylate in the purine nucleotide cycle	
4.3.2.2	succinyladenosine monophosphate	second step common to both de novo and the salvage pathways in purine biosynthesis